These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
382 related articles for article (PubMed ID: 27855620)
21. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Modok S; Mellor HR; Callaghan R Curr Opin Pharmacol; 2006 Aug; 6(4):350-4. PubMed ID: 16690355 [TBL] [Abstract][Full Text] [Related]
22. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847 [TBL] [Abstract][Full Text] [Related]
23. Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance. Karthikeyan S; Hoti SL Anticancer Agents Med Chem; 2015; 15(5):605-15. PubMed ID: 25584696 [TBL] [Abstract][Full Text] [Related]
25. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Wortelboer HM; Usta M; van der Velde AE; Boersma MG; Spenkelink B; van Zanden JJ; Rietjens IM; van Bladeren PJ; Cnubben NH Chem Res Toxicol; 2003 Dec; 16(12):1642-51. PubMed ID: 14680379 [TBL] [Abstract][Full Text] [Related]
26. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition. Gao M; Xu Y; Qiu L J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110 [TBL] [Abstract][Full Text] [Related]
27. Natural products as multidrug resistance modulators in cancer. Kumar A; Jaitak V Eur J Med Chem; 2019 Aug; 176():268-291. PubMed ID: 31103904 [TBL] [Abstract][Full Text] [Related]
28. MRP1 and its role in anticancer drug resistance. Lu JF; Pokharel D; Bebawy M Drug Metab Rev; 2015; 47(4):406-19. PubMed ID: 26541366 [TBL] [Abstract][Full Text] [Related]
29. ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy. Dlugosz A; Janecka A Curr Pharm Des; 2016; 22(30):4705-4716. PubMed ID: 26932159 [TBL] [Abstract][Full Text] [Related]
30. Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance. Li S; Zhang W; Yin X; Xing S; Xie HQ; Cao Z; Zhao B Anticancer Agents Med Chem; 2015; 15(4):423-32. PubMed ID: 25929575 [TBL] [Abstract][Full Text] [Related]
31. Reversing agents for ATP-binding cassette drug transporters. Lee CH Methods Mol Biol; 2010; 596():325-40. PubMed ID: 19949930 [TBL] [Abstract][Full Text] [Related]
32. Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators. Coburger C; Wollmann J; Krug M; Baumert C; Seifert M; Molnár J; Lage H; Hilgeroth A Bioorg Med Chem; 2010 Jul; 18(14):4983-90. PubMed ID: 20598550 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP- binding cassette (ABC) drug transporters. Dantzig AH; Shepard RL; Pratt SE; Tabas LB; Lander PA; Ma L; Paul DC; Williams DC; Peng SB; Slapak CA; Godinot N; Perry WL Biochem Pharmacol; 2004 Mar; 67(6):1111-21. PubMed ID: 15006547 [TBL] [Abstract][Full Text] [Related]
34. Mechanisms of verapamil-enhanced chemosensitivity of gallbladder cancer cells to platinum drugs: glutathione reduction and MRP1 downregulation. Wang H; Li X; Chen T; Wang W; Liu Q; Li H; Yi J; Wang J Oncol Rep; 2013 Feb; 29(2):676-84. PubMed ID: 23229154 [TBL] [Abstract][Full Text] [Related]
35. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives. Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160 [TBL] [Abstract][Full Text] [Related]
36. Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells. Stark M; Assaraf YG Oncotarget; 2017 Jul; 8(30):49973-49987. PubMed ID: 28637003 [TBL] [Abstract][Full Text] [Related]
37. Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Boumendjel A; Baubichon-Cortay H; Trompier D; Perrotton T; Di Pietro A Med Res Rev; 2005 Jul; 25(4):453-72. PubMed ID: 15834856 [TBL] [Abstract][Full Text] [Related]
38. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086 [TBL] [Abstract][Full Text] [Related]
39. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500 [TBL] [Abstract][Full Text] [Related]
40. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer. Filomeni G; Turella P; Dupuis ML; Forini O; Ciriolo MR; Cianfriglia M; Pezzola S; Federici G; Caccuri AM Mol Cancer Ther; 2008 Feb; 7(2):371-9. PubMed ID: 18281520 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]